index - Epidemiology in dermatology and evaluation of therapeutics

DOCUMENTS

95

 

NOTICES

156

 

 

MOTS CLES

Cancer Alitretinoin Biosimilar Pharmaceuticals Arrhythmia Immune-related adverse events Alcohol Atopic dermatitis Psoriatic arthritis Apremilast Apre-milast Méta-Analyse Pharmacovigilance Angiotensin receptor blockers Autoimmunity Anticancer drugs Burden Cardio-oncology Auto-Diagnostic Atrial fibrillation Anxiety Axial spondyloarthritis Drug survival Aging Immunotherapy Prostate cancer Pharmaco-Épidémiologie Antimicrobiens Antimicrobial resistance Biologic drug Angiotensin-converting enzyme inhibitors Ustekinumab Biologic therapy Biomédicaments Anxiété Endocrine toxicity Ankylosing spondylitis Addiction Biologic Psoriasis Antibiotics Quality of life Graft-versus-host disease Arthritis Antimicrobials Antibiotic misuse Drug reaction Management BTK protein Pharmacoepidemiology Antimicrobial Stewardship Bacterial Systematic review Cardiotoxicity ASDAS Sacroiliitis Vigibase® ArtThese Placebo Glucocorticoids Anti-TNF Meta-Analysis Abus d'antibiotiques Beta-lactam antibiotics Cardiomyopathy Immune checkpoint inhibitors Anti-Bacterial Agents Adverse side effects Bacterial rhinosinusitis Acute Myeloid Leukaemia AML Biomarkers Treatment Autoimmune diseases Antibiotic resistance Biologics Spondyloarthritis Dermatology Primary adrenal insufficiency Network meta-analysis Epidemiology Access to care Biological therapy Auto-immune hepatitis Adalimumab Etanercept Adolescent Sipuleucel-T Intensive care Amyloidosis Stability Infliximab COVID-19 Biological Therapy Accelerometer Azathioprine Anti-HCV Direct Acting Antivirals DAA Spondylitis Ethics Pregnancy Albinism Ankylosing

 

 

 

Epidemiology in Dermatology and Evaluation of therapeutics , EA 7379

Adresse

Université Paris-Est Créteil Val de Marne (UPEC)

Campus Centre de Créteil
61 Avenue du Général de Gaulle
94010 Créteil Cedex

Courriel

emilie.sbidian@aphp.fr

Site Internet

 

Rattachement(s)

UFR de Santé

Direction

Émilie SBIDIAN

 

Axe(s) de recherche

 


[legende-image]65[/legende-image] Axe 1 : Comment mieux gérer les patients ayant développé des réactins graves aux médicaments, notamment en leur indiquant comment utiliser correctement les agents


[legende-image]65[/legende-image] Axe 2 : Rechercher les facteurs associés aux effets indesirables et à l'efficacité du médicament

 
 

COLLABORATIONS